Table 1.
Baseline characteristics of the study population
|
Seronegative patients |
All patients |
||||
|---|---|---|---|---|---|
| Casirivimab and imdevimab (n=1633) | Usual care (n=1520) | Casirivimab and imdevimab (n=4839) | Usual care (n=4946) | ||
| Age, years | 63·2 (15·5) | 64·0 (15·2) | 61·9 (14·6) | 61·9 (14·4) | |
| <70* | 1054 (65%) | 943 (62%) | 3389 (70%) | 3454 (70%) | |
| 70–79 | 348 (21%) | 344 (23%) | 936 (19%) | 962 (19%) | |
| ≥80 | 231 (14%) | 233 (15%) | 514 (11%) | 530 (11%) | |
| Sex | |||||
| Men | 995 (61%) | 879 (58%) | 3033 (63%) | 3095 (63%) | |
| Women† | 638 (39%) | 641 (42%) | 1806 (37%) | 1851 (37%) | |
| Ethnicity | |||||
| White | 1325 (81%) | 1254 (83%) | 3779 (78%) | 3822 (77%) | |
| Black, Asian, and minority ethnic | 151 (9%) | 136 (9%) | 596 (12%) | 697 (14%) | |
| Unknown | 157 (10%) | 130 (9%) | 464 (10%) | 427 (9%) | |
| Number of days since symptom onset | 7 (4–10) | 7 (5–9) | 9 (6–12) | 9 (6–12) | |
| Number of days since admission to hospital | 1 (1–2) | 1 (1–3) | 2 (1–3) | 2 (1–3) | |
| Respiratory support received | |||||
| No oxygen received | 182 (11%) | 148 (10%) | 332 (7%) | 309 (6%) | |
| Simple oxygen | 1085 (66%) | 995 (65%) | 2980 (62%) | 3016 (61%) | |
| Non-invasive ventilation | 332 (20%) | 341 (22%) | 1244 (26%) | 1317 (27%) | |
| Invasive mechanical ventilation | 34 (2%) | 36 (2%) | 283 (6%) | 304 (6%) | |
| Previous diseases | |||||
| Diabetes | 403 (25%) | 407 (27%) | 1240 (26%) | 1337 (27%) | |
| Heart disease | 407 (25%) | 398 (26%) | 1038 (21%) | 1061 (21%) | |
| Chronic lung disease | 455 (28%) | 458 (30%) | 1085 (22%) | 1159 (23%) | |
| Tuberculosis | 7 (<1%) | 5 (<1%) | 18 (<1%) | 16 (<1%) | |
| HIV | 7 (<1%) | 4 (<1%) | 24 (<1%) | 22 (<1%) | |
| Severe liver disease‡ | 28 (2%) | 17 (1%) | 69 (1%) | 70 (1%) | |
| Severe kidney impairment§ | 114 (7%) | 114 (8%) | 266 (5%) | 242 (5%) | |
| Any of the above previous diseases | 935 (57%) | 913 (60%) | 2557 (53%) | 2662 (54%) | |
| SARS-CoV-2 PCR test result | |||||
| Positive | 1587 (97%) | 1476 (97%) | 4702 (97%) | 4813 (97%) | |
| Negative | 19 (1%) | 16 (1%) | 42 (1%) | 56 (1%) | |
| Unknown | 27 (2%) | 28 (2%) | 95 (2%) | 77 (2%) | |
| SARS-CoV-2 antibody test result | |||||
| Positive | 0 | 0 | 2636 (54%) | 2636 (53%) | |
| Negative | 1633 (100%) | 1520 (100%) | 1633 (34%) | 1520 (31%) | |
| Missing | 0 | 0 | 570 (12%) | 790 (16%) | |
| Received a COVID-19 vaccine | 128 (8%) | 117 (8%) | 394 (8%) | 418 (8%) | |
| Corticosteroids received | |||||
| Yes | 1481 (91%) | 1399 (92%) | 4530 (94%) | 4639 (94%) | |
| No | 152 (9%) | 118 (8%) | 308 (6%) | 299 (6%) | |
| Not recorded | 0 | 3 (<1%) | 1 (<1%) | 8 (<1%) | |
| Other randomly assigned treatments | |||||
| Azithromycin | 38 (2%) | 43 (3%) | 124 (3%) | 124 (3%) | |
| Colchicine | 364 (22%) | 350 (23%) | 1085 (22%) | 1139 (23%) | |
| Aspirin | 405 (25%) | 372 (24%) | 1339 (28%) | 1389 (28%) | |
| Baricitinib | 139 (9%) | 138 (9%) | 440 (9%) | 422 (9%) | |
Data are mean (SD), n (%), or median (IQR).
*
Includes 11 children (aged <18 years).
†
Includes 26 pregnant women.
‡
Defined as requiring ongoing specialist care.
§
Defined as estimated glomerular filtration rate lower than 30 mL/min per 1·73 m2.